Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02190253 · ClinicalTrials.gov registry record

Seroprevalence of Hepatitis E in People With an Organ Transplant

A clinical trial, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).

Completed
Registry status
447
Enrollment target

NCT02190253 is a clinical trial that has completed, run by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The registered enrollment target is 447 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02190253 has completed, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).

COMPLETED
Registry status
447 participants
Enrollment target

Study Summary

Background: \- The hepatitis E virus causes an acute hepatitis that usually goes away by itself. Researchers in France studied people who received a liver or kidney transplant. They found that hepatitis E may not go away by itself in these people. It becomes chronic. This can cause serious liver disease. More than half the people who had organ transplant who had hepatitis E seemed to get a chronic infection. Researchers want to find out if hepatitis E happens this often in patients who have liver, kidney, or small bowel transplants in the United States. If it does, they want to know why. They want to know if chronic hepatitis E will become an important medical problem. This research might help improve care for people who have a transplant. It also might help researchers prevent the spread of hepatitis E. Objective: \- To see how many patients who have received or are waiting for certain transplants have antibodies to hepatitis E virus. Eligibility: \- Adults over age 18 who have had a liver, kidney, liver and kidney, or small bowel transplant, or are on a waiting list for one. Design: * Participants will be enrolled from 3 transplant centers. * Participants will complete a questionnaire. They will be asked about possible risk factors for hepatitis E exposure. * Participants will have a blood sample drawn through a needle placed in a vein.

Trial Details

FieldValue
Enrollment Target 447 participants
Start Date 2014-07-12
Est. Completion 2019-02-05

What the Registry Record Tells You About NCT02190253

The ClinicalTrials.gov registry entry for NCT02190253 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 447 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 0 interventions.

NCT02190253 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02190253 about?

NCT02190253 is a clinical study titled "Seroprevalence of Hepatitis E in People With an Organ Transplant". Background: \- The hepatitis E virus causes an acute hepatitis that usually goes away by itself. Researchers in France studied people who received a liver or kidney transplant. They found that hepatitis E may not go away by itself in these people. It becomes chronic. This can cause serious liver di...

What is the current status of trial NCT02190253?

This trial is currently completed. The enrollment target is 447 participants. The study started on 2014-07-12. Estimated completion is 2019-02-05.

Who is sponsoring clinical trial NCT02190253?

This trial is sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.